Navigation Links
NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
Date:1/10/2008

PHOENIX, Jan. 10 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran (SRB), nutrient research and technology, announced today that it has formed two joint ventures with HerbalScience Singapore Ltd Pte, a company that produces standardized botanical extracts for functional food and nutraceutical uses, and identifies novel chemistries for drug development through the application of its proprietary platform technology. The parties will establish two companies, one for nutraceutical products and functional food ingredient development from SRB and one for drug discovery from SRB.

Under the terms of the agreements, NutraCea will have an 80% interest in Rice Science, a newly formed limited liability company that will develop certain extracts targeted for specific health conditions. Rice Science has identified three specific areas of health that it will pursue: Diabetes, Arthritis and Immunity. The second newly formed company, Rice Rx, will be a limited liability company owned 50/50 by HerbalScience and NutraCea. It will advance drug discovery from SRB for licensing to life science and pharmaceutical companies.

Brad Edson, Chief Executive Officer of NutraCea commented, "Our ongoing clinical research continues to validate our beliefs regarding the inherent value of our proprietary products for various applications related to certain disease specific states such as joint health, immune response, diabetes, cardiovascular disease and more. We know that stabilized rice bran contains a rich bounty of natural compounds at therapeutic levels. We believe by isolating these specific elements, we can create quantifiable isolates that have the potential to be measurably effective in dealing with some of the most serious health threats that we face today. Additionally, many botanicals have been the basis for pharmaceutical drugs."

Robert Gow, Chairman and CEO of HerbalScience said, "We are pleased to partner w
'/>"/>

SOURCE NutraCea
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NutraCea Announces Conference Call to Report Second Quarter Financial Results
2. NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14
3. NutraCea Appoints Financial Relations Board as New Investor Relations Firm
4. Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i
5. Overwhelming Majority of Michigan Residents Favors Individual Health Insurance Market Reforms Supported by Blue Cross Blue Shield of Michigan
6. DenteMax Forms Business Alliance With MEDILINQ
7. CJ Transforms His Functional Fitness Program Into an Additional Resource for the Hurricane Katrina Survivors
8. The Multiple Sclerosis Association of America Transforms Website with a New Look and New Technology
9. Premier Micronutrient Forms Strategic Partnership With EAR Inc.
10. Global Health Support Service Benchmark Study to Combat Growing Healthcare Costs and Prepare for Likely Health Care Reforms
11. In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 , ... Based in Beverly ... fleet of truly superb luxury vehicles based on which of the latest and greatest ... the latest step forward in pursuit of this goal: a 2015 Rolls Royce ...
(Date:9/2/2015)... DC (PRWEB) , ... September 02, 2015 , ... Telehealth ... American Well Corp., contracted to handle the telehealth services of more than 12 Blues ... Cross and Blue Shield Plans takes a look this growing trend, interviewing executives at ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... Fort Lauderdale, FL (PRWEB) , ... September 02, ... ... cost for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision ... with hospitalized Medicare patients – is likely to average approximately $71,000 or roughly ...
(Date:9/2/2015)... Bryn Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Location: Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, ... justCommunity, Inc., will host a day-long seminar featuring New York Times best-selling author Sam ...
Breaking Medicine News(10 mins):Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2
... women,s risk gets even smaller 10 years after stopping ... News) -- Women taking oral contraceptives are at a ... decade after stopping the pill even this very small ... that finding doesn,t change the recommendation for women to ...
... year over year growth driven by Loestrin 24 and Taclonex; Company ... updates full year 2007 financial guidance, ST. ... today announced its results for the quarter ended,September 30, 2007. Revenue ... of 16.3%, over the prior year quarter. The,primary drivers of the ...
... Highlighted by Continued Momentum in Global Commercialization, Program for Once-Daily ... ... III Study -, LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - ... the third quarter of fiscal,2007, ended September 30, 2007. All ...
... event in 2007, net loss stable ... otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ - ... company, today announced financial results for the first,quarter of ... "We are also focused on the successful completion of ...
... Pharmaceutical product teams,have the power to make ... The problem is,launch teams often lack the right ... only produce a sub-optimal launch. In fact, ... and cross-functional team work are key ingredients,during product ...
... Support Continued Advancement of Novel Technology and ... ... Inc., a,privately-held therapeutic antibody product company, today announced that,it has raised ... A/S.,Additional investors participating significantly in the round were Frazier,Healthcare Ventures and ...
Cached Medicine News:Health News:Pill Poses Little Cervical Cancer Risk 2Health News:Pill Poses Little Cervical Cancer Risk 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2007 14
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
(Date:9/2/2015)... Sept. 2, 2015  Research and Markets ( ... "An Introduction to the Medical Devices Directive ... to their offering. This seminar ... device legislation. It will explain the Directives and ... Bodies, how to choose one and outline what ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( ... PharmaBiotech,s new report "Drug Delivery in Central ... to their offering. Advances ... BBB have opened new avenues and possibilities for ... or transport systems, enzymes, and receptors that control ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... Dec. 28, 2011 Reportlinker.com announces ... is available in its catalogue: ... Diabetes Care Devices Market Outlook to ... http://www.reportlinker.com/p0739469/South-and-Central-America-Diabetes-Care-Devices-Market-Outlook-to-2017--Glucose-Monitoring-and-Insulin-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ...
... 2011 BNA Books , a division of specialized ... publication of the 2011 Supplement to ... domestic and international developments in pharmaceutical patent law. ... Law, Second Edition  tracks legal developments within the PTO, the ...
Cached Medicine Technology:South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 2South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 3South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 4South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 5South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 6South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 7South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 8South and Central America Diabetes Care Devices Market Outlook to 2017- Glucose Monitoring and Insulin Delivery 9BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition" 2BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition" 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: